Clinical features and prognostic factors of cervical villoglandular adenocarcinoma.

Background Villoglandular adenocarcinoma is a rare sub- type of cervical adenocarcinoma. Objective To analyze the clinicopathological features and evaluate the prognosis of patients with villoglandular adenocarcinoma of the cervix. Methods Patient characteristics, procedure, pathology, and surgical outcomes were retrospectively reviewed in patients with villoglandular adenocarcinoma between November 2006 and June 2019 from multiple centers in China. In order to explore the difference between villoglandular adenocarcinoma and routine adenocarcinoma, patients (FIGO 2009 stage IA1-IB2) who had complete data during the same time period were included. Results A total of 60 patients with villoglandular adenocarcinoma and 104 with standard adenocarcinoma were included. The median age of the patients with villoglandular adenocarcinoma was 42 years (range 27--68). The most common 2009 FIGO stage was IB1 in 39 (65%) patients with villoglandular adenocarcinoma. A total of 23 patients underwent laparoscopic surgery (two total hysterectomies, 21 radical hysterectomies) and the other 37 patients underwent laparotomy (three total hysterectomies, 34 radical hysterectomies). A total of 56 patients underwent lymphadenectomy and three (5.4%) had positive lymph nodes. Fifteen (25%) patients had one or both ovaries preserved. Seven patients were lost to follow- up. The median follow- up time for the entire group was 50.2 months (range 5.1--154.6). No deaths or recurrences occurred. Excluding six patients with FIGO 2009 stage II, the 5- year disease- free survival of the 47 patients with villoglandular adenocarcinoma with FIGO 2009 stage I for whom there was follow- up, was significantly higher than that of the 104 patients with standard cervical adenocarcinoma (100% vs 92.2%, logrank p=0.039). However, the 5- year overall survival of the two groups did not differ (100% vs 95.7%, log- rank p=0.11). Conclusion Villoglandular adenocarcinoma has a favorable prognosis. Further studies are needed to provide more details of treatment strategies and prognosis. [ABSTRACT FROM AUTHOR]